Currently, interventions targeting angiogenesis have become a new direction in BC treatment, such as anti-VEGF drugs (e.g., bevacizumab) and tyrosine kinase inhibitors (TKIs) (40–42). This evidence concerns the gene VEGFA and breast cancer.